[1] Yang JD, Hainaut P, Gores GJ, et al. A global view of hepatocellular carcinoma: trends, risk, prevention and management[J]. Nat Rev Gastroenterol Hepatol, 2019,16:589-604. [2] 陈悦,徐杰茹,杨钟泽, 等. 2005—2015年全国肝癌发病趋势分析[J].实用预防医学,2021,28:1180-1184. [3] 吴娜,王东,白咸勇.细胞自噬与肝细胞癌的研究进展[J].基础医学与临床,2021,41:1514-1517. [4] Cai Q, Zhu M, Duan J, et al. Comprehensive analysis of immune-related prognosis of TK1 in hepatocellular carcinoma[J]. Front Oncol, 2022,11:786873.doi:10.33891/fonc.2021.786873. [5] Krishnan MS, Rajan Kd A, Park J, et al. Genomic analysis of vascular invasion in HCC reveals molecular drivers and predictive biomarkers[J]. Hepatology, 2021,73:2342-2360. [6] Xin L. EZH2 accompanies prostate cancer progression[J]. Nat Cell Biol, 2021,23:934-936. [7] Ritchie ME, Phipson B, Wu D, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies[J]. Nucleic Acids Res, 2015,43:e47.doi:10.1093/nav/gkv007. [8] Yu G, Wang LG, Han Y, et al. clusterProfiler: an R package for comparing biological themes among gene clusters[J]. OMICS, 2012,16:284-287. [9] Ramírez F, Dündar F, Diehl S, et al. deepTools: a flexible platform for exploring deep-sequencing data[J]. Nucleic Acids Res, 2014, 42: W187-W191. [10] Lau-Corona D, Bae WK, Hennighausen L, et al. Sex-biased genetic programs in liver metabolism and liver fibrosis are controlled by EZH1 and EZH2[J]. PLoS Genet, 2020,16:e1008796. doi:10.1371/journal.pgen.1008796. [11] Duan R, Du W, Guo W. EZH2: a novel target for cancer treatment[J]. J Hematol Oncol, 2020,13:104. doi:10.1186/s13045-020-00937-8. [12] Chen G, Fan X, Li Y, et al. Promoter aberrant methyla-tion status of ADRA1A is associated with hepatocellular carcinoma[J]. Epigenetics, 2020,15:684-701. |